Morrison Foerster is an international law firm with lawyers practicing throughout the United States, Asia, and Europe. Click to discover more.

mofo_share_image.jpg

Morrison Foerster

common-default.jpeg

Terms / Notices

Cookies

Privacy Policy

Reporting Hotline

Attorney Advertising

Alumni

  Linkedin

MoFo LinkedIN

  Facebook

MoFo Facebook

YouTube

MoFo Youtube

Morrison Foerster - Footer

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

You have not solved the recaptcha challenge yet or session expired, try again.

Email Disclaimer

Disclaimer

Unsolicited e-mails and information sent to Morrison Foerster will not be considered confidential, may be disclosed to others pursuant to our <a href="https://www.mofo.com/about/privacy-policy.html">Privacy Policy</a>, may not receive a response, and do not create an attorney-client relationship with Morrison Foerster. If you are not already a client of Morrison Foerster, do not include any confidential information in this message. Also, please note that our attorneys do not seek to practice law in any jurisdiction in which they are not properly authorized to do so.

Feedback

mofo-logo-2022.svg

People

Capabilities

Resources

About

Community

Offices

Careers

Stay Connected

According to Deloitte’s 2022 Global Life Sciences Report, 2023 will be challenging and transformative for life sciences companies.

<h3>Sorry, we weren’t able to find the terms you entered.</h3>Please try a different term or keyword.

People

Capabilities

Resources

Not Found Cards

According to Deloitte’s 2022 Global Life Sciences Report, 2023 will be challenging and transformative for life sciences companies.<ul><li dir="ltr">Swift shifts to more data-driven approaches across the value chain of the industry brings data security in multijurisdictional operations to the top of investors’ minds.</li><li dir="ltr">Out of growing geopolitical concerns, how to manage IPs so that they can be in neutral jurisdictions and how to carefully manage data export has been heatedly discussed and will continue to be a key topic.</li><li dir="ltr">Furthermore, AI is reshaping the industry in all areas from drug discovery and clinical trials to patient experience and pharmacovigilance. How companies could effectively make use of AI is a key to success in the year to come.</li><li dir="ltr">The past three years of the pandemic has brought huge financial stress to life sciences companies; therefore, innovative ways to monetize assets will position the investors to a more advantageous role. </li><li dir="ltr">As companies are moving towards commercialization of their products, identifying and mitigating potential risks of patent infringement lawsuits is central to their business strategy.</li></ul>In this session, we bring a panel of legal leaders to discuss the above topics to help life sciences companies navigate through the turmoil. The panel will be moderated by Morrison Foerster Partner Janet Xiao, Head of the firm’s China Life Sciences Group; with MoFo Partner Chuan Sun, a highly regarded technology transaction lawyer; Partner Rongjing Zhao, an experienced M&A lawyer, and MoFo Partner Lily Li, who frequently advises clients on high-stakes patent litigations. <hr>

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

Sign Up

Dr. Janet (Jian) Xiao is a leading patent attorney specializing in global patent procurement, patent portfolio management, and IP strategic planning for life sciences and biopharmaceutical companies. Recognized by Chambers USA and Chambers Global as a top-ranked intellectual property lawyer, Dr. Xiao is highly sought after by biotech and pharmaceutical innovators worldwide for patent prosecution, patent strategy, and life sciences IP counsel.Dr Xiao’s clients range from large renowned multinational companies to emerging startups worldwide. She advises her clients on patent matters relating to various technologies including antibody therapeutics, cell therapeutics, nanomedicine, gene therapy, drug delivery systems, diagnostics, and nutraceuticals. Recognized for her deep understanding of the industry and knowledge of IP, Janet is known for developing and strengthening her clients’ complex patent portfolios to maximize their commercial value and success. She has been instrumental on the strategy development for multibillion-dollar patent portfolios for pharmaceutical clients, and adds tremendous value by combining her creative legal skills, keen business acumen, and solid foundation in science. As impressed clients noted to Chambers, “Janet consistently delivers a very high level of client service and exhibits strong commercial awareness and vision.”Janet works extensively in performing IP due diligence reviews in the contexts of VC investments, technology transactions, mergers and acquisitions, as well as marketing and manufacturing clearance for biopharmaceutical products. She works closely with her clients to assess potential risks and devise preemptive risk-management strategies for their product development and investments. She has led hundreds of IP due diligence projects, and is most notable for her deep knowledge about patent landscapes in the fields of cancer immunotherapy, gene editing, next-generation sequencing, liquid biopsy, antibody manufacturing, and medical devices. Janet works synergistically with patent litigators in the event of legal challenges by third-party competitors or vice versa, and is frequently called upon to represent clients in litigation and post-grant proceedings.Janet is among the very few IP attorneys in the world who are both equipped with solid skills in global strategic IP management and knowledgeable about IP issues unique to China and Chinese clients, and she has been the go-to counsel for IP issues in U.S./China cross-border transactions and operations in China. As Chambers Global 2024 notes, “She is great, very strong and thoughtful. She has a very large contingent of Chinese companies.”Janet is the Head of China Life Sciences at Morrison Foerster and served as co-chair of the firm’s global Life Sciences Group from 2016 to 2019. Chambers Global states that Janet “is recognized for her knowledge of IP law relating to the life sciences arena,” and that she is “held in high regard by sources for her deep understanding of the pharmaceutical and biotech industries.” In a recent edition of Chambers Global, a client remarks, “Janet is a wonderful lawyer. She is very experienced in advising life sciences clients doing business in China and the US. She is highly responsive and always gives practical advice. Her IP expertise adds tremendous value to our business.”

肖荐（Janet Xiao）博士的业务侧重于为生命科学公司处理在全球范围内的专利采购、专利组合管理和战略策划事宜。肖博士服务的客户范围广泛，包括大型跨国生物制药公司，例如赛尔基因公司（Celgene）和基因泰克公司（Genentech），也包括全球范围的新兴创业公司。她经常就与各种技术有关的专利事宜向客户提供法律意见，其中涉及的技术包括抗体疗法、细胞疗法、纳米医学、基因疗法、给药系统、诊断和和营养学等。来自全球的创新者纷纷向肖博士寻求专利申请和专利战略的法律咨询，这一点也得到了《钱伯斯指南》的认可。她帮助客户开发和加强其复杂的专利组合，从而为客户实现最大的商业价值。在为制药行业的客户制定数十亿美元专利组合的战略方面，肖博士发挥着重要的作用。《钱伯斯指南》曾引用客户评价称，“肖博士是我曾合作过的律师当中知识最渊博、效率最高的一位律师。她能很好地将专利组合的历史信息用于全球专利申请问题上。”肖博士针对风险投资、技术交易、并购和生物医药产品的市场推广与生产许可事宜开展广泛的知识产权尽职调查审查工作。她协助世界上一些最成功的生物制药公司和投资者，为其产品开发和投资评估潜在风险，并制定先发制人的风险管理策略。她曾牵头处理过数百个知识产权尽职调查项目，并凭借自己对癌症免疫治疗、基因编辑、新一代测序、液体活检、抗体制造和医疗设备领域的专利方面的深厚知识而闻名。肖博士时常与专利诉讼律师合作，处理由第三方竞争者提出的法律质疑，或对第三方竞争者提出的法律质疑，她还经常受聘代表客户处理专利诉讼和授予后程序。肖博士是美富中国生命科学业务组主管，她曾在2016至2019期间担任美富全球生命科学业务组的联席主管。肖博士是全球为数不多的既拥有很强的全球战略性知识产权管理技能，同时又对中国和中国客户独特的知识产权问题具有深刻理解的知识产权律师之一，她一直是处理中美跨境交易和在中国境内经营中所涉知识产权问题的首选律师。《钱伯斯全球指南》称赞她是一位优秀的知识产权律师，“她因处理与复杂跨境交易有关的知识产权问题工作而知名，经常代表中国客户处理这方面的事宜” 。在近期一版《钱伯斯全球指南》中，某客户评价称，“肖博士在为于中国和美国开展业务的生命科学客户提供法律意见方面，有非常丰富的经验。她非常负责而且总是提供切实可行的法律意见。她在知识产权方面的专业意见为我们的业务增添了巨大价值。”自2005年以来，肖博士一直积极参与北美华人生物医药协会（CABS）的领导工作。该协会是一家非营利组织，致力于成为连接中美两国生命科学领域的纽带。肖博士在2011至2012年间担任该协会主席。她还是百华协会（BayHelix）的成员。百华协会是一家非营利组织，由全球生命科技和医疗保健产业领域的华人精英组成。

Janet Xiao

Partner

Chuan Sun is Managing Partner of the Shanghai and Hong Kong offices.Chuan focuses his practice on cross-border M&A transactions; sophisticated technology, media, and telecom (TMT) transactions; and complex IP/commercial matters across Greater China.With more than 20 years of experience in both Asia and the U.S., Chuan regularly advises multinational corporations, state-owned enterprises, private companies, and PE/VC firms in complex cross-border M&A transactions, joint ventures, strategic alliances, and business separation transactions.Chuan has extensive experience in complex corporate-commercial and technology transactions across the Fintech, e-commerce, and broader TMT sectors. His work covers payment technology, eKYC, credit technology, blockchain, e-platform arrangements, R&D, co-development, technology collaborations, and IP licensing. He also advises on strategic outsourcing, manufacturing, distribution, supply, and franchising arrangements across various industries.Chuan regularly counsels clients on cutting-edge technology and IP regulatory matters, including Fintech, data privacy, cybersecurity, data localization, cross-border data transfers, cloud computing, telecommunications, telematics, and third-party payment services.Prior to joining MoFo, he worked in the Hong Kong office of a Magic Circle firm and the Chicago office of another leading international firm.Chuan co-authored the Hong Kong & mainland China chapters of Getting the Deal Through – Telecoms and Media, 2014, 2015 & 2016; the Hong Kong & mainland China chapters of Getting the Deal Through: Market Intelligence – Telecoms and Media, 2015; and the Hong Kong chapter of Sourcing World 2nd Edition 2015.Chuan is fluent in Mandarin and English.“Chuan Sun has a wealth of knowledge on his clients’ existing products and services offerings and a good understanding of what terms they are or are not willing to accept. This helps tremendously with contract negotiations.”“Chuan Sun has extensive experience in the technology space. Many other competitor firms in the technology space are not really pure IT lawyers, as they are more focus on privacy and trade marks or other related fields, as opposed to technology contracts such as SAP or Microsoft software license agreements. A normal general commercial lawyer would not be able to identify the same issues or raise the right questions, as they are not equipped with the technology know-how of the products and services, their benefits, and general industry standard terms and trending patterns in the market.” Legal 500 Asia Pacific 2020<h4>Representative Experience:</h4><ul><li>CPE, a Chinese alternative investment firm, in connection with its US$350 million joint venture with Restaurant Brands International (RBI), one of the world's largest multinational fast food holding company, to operate Burger King in China which has around 1,250 restaurants in total. This transaction is one of the most significant private equity-led transactions in China’s consumer sector in 2025.</li><li>OcuMension Therapeutics (HKSE: 01477), a Hong Kong Stock Exchange listed ophthalmic pharmaceutical platform in China in its acquisition of substantial assets valued at HK$1.28 billion (approximately US$165 million) from Alcon Inc., a global leader in eye care. The transaction involves asset purchase, global license, transition services and manufacture and supply arrangement and constitutes a very substantial transaction of OcuMension.</li><li>Ascendent Capital Partners in its US$1.66 billion privatization of Hollysys Automation Technologies Ltd. (NASDAQ: HOLI), a leading international automation control system solutions provider. This is a rare transaction where a PE fund successfully acquires a US-listed Chinese company without forming a consortium with controlling shareholder or management. It is also the first and only U.S. take-private of a BVI-incorporated company involving a dissenter process. </li></ul><ul><li>Leading Global, China-Headquartered Fintech Company. Advise the company in connection with its first provision of blockchain and Real World Asset solutions in the fintech industry to a leading Chinese securities company for the latter’s first launch of structured product tokens, enabling secure, transparent, tamper-proof transactions for fixed-income and principal-protected tokenized products linked to US equity ETFs.</li><li>Leading Global, China-Headquartered Fintech Company. Advise the company in connection with the international expansion of its various business operations that are based on cutting-edge technologies, including blockchain and crypto, into multiple jurisdictions. </li></ul>

孙川是美富上海办公室和香港办公室的管理合伙人。孙川律师的执业领域集中在大中华区的跨境并购交易，复杂的技术、媒体和电信(TMT)交易以及复杂的知识产权/商务事宜。孙律师在亚洲和美国有20多年工作经验，他经常代理跨国公司、国有企业、私人企业和私募股权/风险投资机构处理复杂的跨境并购交易、合资、战略联盟和业务拆分等交易。孙律师在战略性的公司商务和技术交易方面也拥有极为丰富的经验，包括外包、制造、分销、供应与特许经营安排，以及跨行业知识产权许可安排等。他在TMT和知识产权监管方面的经验包括电信、电子商务、互联网、网络安全、数据隐私、云计算以及车联网。在加入美富前，孙律师在一家 “魔法圈”律所(Magic Circle)的香港办事处和另一家领先的国际律所的芝加哥办事处工作。孙律师与他人合著了2014，2015和2016版《让交易推进下去––电信与媒体》(Getting the Deal Through – Telecoms and Media)中的香港和中国大陆章节，2015年版《让交易推进下去：市场情报––电信与媒体》(Getting the Deal Through: Market Intelligence – Telecoms and Media)中的香港和中国大陆章节，以及2015年《采购世界》第二版(Sourcing World 2nd Edition)的香港章节。2018年《亚太法律500强》指出“孙川律师十分高效、负责和实际。他非常擅长处理IT协议，包括软件许可和IT采购合同的相关事宜。他也十分善于处理跨境TMT交易。”孙律师精通普通话和英语。<h4>具有代表性的交易 </h4><ul><li>代表中国另类投资公司CPE源峰 就其与世界上最大的餐饮公司之一餐饮品牌国际集团（Restaurant Brands International，简称 RBI）成立价值3.5亿美元的合资企业。该合资企业将负责汉堡王在中国的运营，目前在全国拥有约 1,250 家餐厅。本次交易是 2025 年中国消费行业中由私募股权基金主导的最具代表性交易之一。</li><li>代表香港上市的中国眼科制药平台欧康维视生物医药(HKSE: 01477)处理其收购全球眼科护理领域的领导者爱尔康公司价值 12.8 亿港元（约 1.65 亿美元）重大资产的事宜。交易涉及资产收购，以及全球许可、过渡期服务、生产和供应安排等，是欧康维视的一项非常重大交易。</li><li>代表上达资本处理其以16.6亿美元对和利时自动化技术有限公司（纳斯达克证券交易所股票代码：HOLI）进行私有化事宜。和利时是一家领先的国际自动化控制系统解决方案提供商。这是一宗罕见的交易。在这宗交易中，私募股权基金在未与控股股东或管理层组建财团的情况下，就成功收购了在美国上市的中国公司。这也是首宗且唯一一宗涉及异议股东程序的，在英属维尔京群岛注册成立的公司的美国上市公司私有化交易。</li><li>代表一家总部位于中国的全球领先金融科技公司首次为金融科技行业提供区块链及现实世界资产（RWA）解决方案，协助一家中国头部证券公司首次发行结构化产品代币。该方案为挂钩美国股票ETF的固定收益及保本型代币化产品提供了安全、透明且防篡改的交易支持‌。</li><li>代表一家总部位于中国的全球领先金融科技公司处理基于区块链和加密货币等尖端技术开展的各项业务在多个司法管辖区进行国际扩张的事宜。</li></ul>

Chuan Sun

Managing Partner, Shanghai and Hong Kong

Lily Li is a partner in the firm’s Intellectual Property practice and Head of Litigation in the Palo Alto office. She represents technology companies in high-stakes patent, trade secret, copyright, trademark, and licensing disputes, as well as complex commercial matters. With an engineering background, published research in artificial intelligence, and prior in-house semiconductor leadership experience, Lily brings technical fluency and seasoned judgment to complex disputes and has led and tried bet-the-company cases. Her practice spans state and federal courts, the International Trade Commission, arbitration tribunals, the U.S. Patent and Trademark Office, and cross-border proceedings. She has experience in technologies including semiconductors, artificial intelligence, software and hardware systems, autonomous driving, aviation, wireless communications, medical devices, and pharmaceuticals.Before entering private practice, Lily served in an in-house leadership role at a semiconductor company, leading patent prosecution, licensing strategy, and global intellectual property portfolio development.She maintains an active pro bono practice focused on human rights and educational equity. She helped lead the team in Cayla J. v. State of California, which secured a historic $2 billion settlement addressing pandemic-related learning loss.Lily earned her bachelor’s degree in electrical engineering and conducted graduate research in artificial intelligence, publishing in IEEE Transactions on Neural Networks. She is admitted to practice in California, before the U.S. Patent and Trademark Office, and the U.S. Court of Appeals for the Federal Circuit.

ChinaBio® Partnering Forum: Top 5 Risks and Opportunities to Watch in China Life Sciences in 2023

20 Sep 2023 1:30 PM - 2:30 PM HKT